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Purpose: The aim of this retrospective study is to present data on clinical significance of hypo-
natremia in an unselected contemporary patient population with small cell lung cancer (SCLC)
with limited disease (LD) and extensive disease (ED).
Patients and methods: Our electronic database was searched for patients with newly diag-
nosed SCLC from June 2004 to December 2008. 395 cases were identified. We collected data
on patient characteristics including clinical performance status, serum sodium values, serum
LDH values, metastatic sites, chemotherapy regimens and response, radiotherapy and survival.
Results: Hyponatremia (sodium <135 mmol/l) was present in 18.9% of all cases. Severe hypo-
natremia (sodium <129 mmol/l) was detected in 8.8%. Hyponatremia was present in 58 out of
241 (24%) patients with ED SCLC and 17 of 154 (11%) patients with LD SCLC. Hyponatremia was
associated with significantly shorter median survival (SCLC all patients: 9.0 vs. 13.0 months,
p < 0.001, LD SCLC: 9.0 vs. 17.0, pZ 0.050, ED SCLC 9.0 vs. 10.0, pZ 0.135). After adjustment
for age, gender, LDH and performance status hyponatremia was an independent predictor of
mortality in patients with ED and LD SCLC.
Conclusion: According to the extensive statistical analyses in our comprehensive unselected
patient population, hyponatremia seems to constitute an independent prognostic factor in
patients with SCLC.
ª 2012 Elsevier Ltd. All rights reserved.Introduction
Lung cancer is still the leading cause of death in patients
with cancer.1 It accounts for over 1,100,000 deaths102 6010; fax: þ49 4102 601343.
l.com (A. Hermes).
2 Elsevier Ltd. All rights reservedworldwide every year. 39,500 patients died of lung cancer
in Germany in 2004.2 15e20% of all cases are diagnosed
with small cell lung cancer (SCLC) with slightly decreasing
frequency over the last 20 years.3 SCLC is an aggressive.
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60%. Median survival is only 6e8 weeks without treatment.4
When chemotherapy is applied, 9e11 months are usually
reached.5e8 Median survival with combined chemo-
radiotherapy is 18e20 months in patients with limited dis-
ease.9e11 22e27 months can be achieved by use of
hyperfractionated radiotherapy in selected patients at the
expense of more treatment-related toxicities and poten-
tially negative influence on quality of life.12
The most important prognostic factors in SCLC are
disease stage, clinical performance status (PS) and lactate
dehydrogenase (LDH).13,14
Hyponatremia in SCLC is the clinical manifestation of the
paraneoplastic syndrome of inadequate ADH secretion
(SIADH, SchwartzeBartter syndrome). SIADH is one of the
typical paraneoplastic syndromes in SCLC.15 Symptoms of
hyponatremia include nausea, fatigue, disorientation,
headache and muscle cramps; severe hyponatremia can
lead to seizures. Other possible causes of hyponatremia at
least in elderly patients with SCLC are chronical heart
failure, nephritic syndrome and volume depletion. In iso-
volemic patients increased release of ADH can be caused by
several medications as diuretics, ACE-inhibitors and selec-
tive serotonin re-uptake inhibitors. Adrenal or hypophyseal
deficiency can also lead to hyponatremia.
The role of hyponatremia as prognostic factor in SCLC
remains unclear. Several retrospective analyses yielded
conflicting results with some evidence for low sodium levels
being a negative prognostic factor.16e18 However, this could
not be confirmed in other studies.19e21
Our retrospective analysis was carried out in order to
shed more light on the significance of hyponatremia as
prognostic factor in a contemporary patient population
with SCLC.Table 1 Patient characteristics of 395 cases.
Age < 60 135 (34%)
Age 61e70 161 (41%)
Age > 70 99 (25%)
Male 240 (61%)
Female 155 (39%)
Limited disease 154 (39%)
Extensive disease 241 (61%)
Performance status 0e1 331 (84%)
Performance status 2e3 64 (16%)
Serum sodium 135 mmol/l 320 (81%)
Serum sodium 134e130 mmol/l 40 (10%)
Serum sodium 129 mmol/l 35 (9%)
LDH < 225 U/l 183 (46%)
LDH  225 U/l 212 (54%)Patients and methods
We searched the electronic database of our department for
patients with newly diagnosed SCLC from June 2004 to
December 2008. SCLC was confirmed by histology or
cytology in all cases.
All patients with newly diagnosed SCLC had a complete
history and physical examination taken. Performance status
was evaluated at base line. A staging procedure was per-
formed including bronchoscopy, CT-scan of the chest and
upper abdomen, MRI or CT-Scan of the brain, bone scan and
a comprehensive laboratory panel including hematologic,
renal and hepatic function tests and LDH. In patients with
clinical diagnosis of LD SCLC, a bone marrow specimen was
obtained.
We collected data on age, disease stage, date of initial
diagnosis, survival, performance status, serum sodium
values, serum levels of lactate dehydrogenase, metastatic
sites, chemotherapy regimens and response (complete
response, partial response, stable disease and progressive
disease).
Serum sodium values were measured by use of Ion
Selective Electrodes with automated specimen dilution
(Cobas Integra 800, Roche).
Hyponatremia was defined as serum sodium values
below 135 mmol/l. Severe hyponatremia was present ifsodium values were measured at or below 129 mmol/l.22 As
clinical symptoms are rare in patients with SCLC and
hyponatremia, we did not include them into classification
of the severity of hyponatremia. Fatigue is often seen in
patients with SCLC with or without concomitant hypona-
triemia and is usually not clearly attributable.
First-line therapy was performed with platinum-based
regimens. Cisplatin was dosed at 75 mg/m2 iv day 1,
carboplatin at Calvert AUC5 iv day 1 and etoposide at
140 mg/m2 iv for 3 days. Maximum number of cycles was 6.
Thoracic radiotherapy (TRT) was typically given over 5
weeks with cumulative doses ranging from 50 to 55 Gy.
Prophylactic cranial irradiation (PCI) was usually adminis-
tered with 30 Gy over a period of 2 weeks. TRT was
employed in 72% of all patients with LD SCLC, PCI in 33%. In
the second-line setting, topotecan was given at 1.5 g/m2 iv
day 1 through 5. Doxorubicin was administered intrave-
nously at 50 mg/m2 and cyclophosphamide at 1000 mg/m2.
About 15% of all patients were treated within clinical trials.
Response was evaluated with CT-scans in all patients
using RECIST (response criteria in solid tumors).23 Response
of three patients who died after the first cycle of chemo-
therapy was deemed as progressive disease.
The method of Kaplan and Meier24 was used to calculate
survival curves. To assess the statistical significance of
differences between the crude survival curves, we per-
formed log-rank tests. Multivariate testing with adjust-
ments for age, gender, LDH and performance status for
patients with ED and LD SCLC was done by Cox regression
analyses.
Results
395 cases were identified. LD SCLC was present in 154
patients (39%), ED SCLC in 241 (61%). Plasma sodium values
were available in all patients. Median sodium value was
137 mmol/l (range 114e149 mmol/l). Table 1.
75 out of 395 patients (18.9%) had pre-treatment serum
sodium values below 135 mmol/l. Mild hyponatremia
(130e134 mmol/l) was present in 40 (10.1%) of these cases.
Severe hyponatremia (sodium value at or below 129 mmol/
l) was documented in the remaining 35 patients (8.8%).
Hyponatremia was present in 58 out of 241 (24%) patients
with ED SCLC and 17 of 154 (11%) patients with LD SCLC.
Table 3 Response rate in all patients with SCLC (both LD
and ED): normal versus subnormal sodium values (mmol/l).
Response Sodium 135
n Z 320
Sodium 134
n Z 75
p-Valuea
Complete
response
30 (9.4%) 3 (4.0%) 0.130
Partial response 201 (62.8%) 48 (64.0%) 0.848
Response rateb 231 (72.2%) 51 (68.0%) 0.470
Stable disease 45 (14.1%) 7 (9.3%) 0.276
Progressive
disease
44 (13.8%) 17 (22.7%) 0.054
a chi-square test.
b Response rate: sum of complete and partial responses.
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not seen comparing the cohorts with normal vs. subnormal
plasma sodium values. Patients with LD SCLC and hypona-
tremia were given sequential thoracic radiotherapy in 71%
and PCI in 47%. For cases with normal sodium values,
thoracic radiotherapy was administered in 57% and PCI in
31%. We did not consider radiation therapy as possible
confounding factor, as the treatment was begun after
chemotherapy in all cases. Cisplatin was given 7 patients
with hyponatremia. Serum creatinine did not change more
than 0.1 mg/dl in these cases and sodium values were rising
in all patients. Thus, there is no evidence for cisplatin
treatment being a confounding factor in our series.
We performed additional analyses with regard to local-
ization of metastases and number of metastatic sites in
patient groups with normal versus subnormal sodium
values. Liver metastases were significantly more frequent
in patients with subnormal sodium values (55 vs. 39%,
pZ 0.028). Regarding number of metastatic sites there was
a trend toward more metastatic sites in patients with
subnormal sodium values. Table 2.
In the 320 patients with normal sodium values, response
rate (RR)was not statistically significant higher than in the 75
cases with subnormal sodium values (72.2 vs. 68.0%,
p Z 0.470). However, progressive disease as result of first
line treatmentwasmore frequent in patientswith subnormal
sodium values (22.7 vs. 13.8%, pZ 0.054). Table 3.
Median survival in the entire group of patients with SCLC
was significantly shorter in patients with subnormal sodium
values (9 vs. 13 months, p < 0.001). In subset analysis of
patients with ED SCLC, there was a non-significantly
reduced median survival in patients with subnormal
sodium values not adjusted for confounders (9 vs. 10
months, p Z 0.135). In LD SCLC though, there was
a significantly shorter survival (9 vs. 17 months, pZ 0.050)
when subnormal sodium levels were present. Table 4,
Fig. 1. In multivariate Cox regression analyses hypona-
tremia was an independent predictor of mortality after
adjustment for age, gender, LDH and performance status in
patients with ED and LD SCLC. Table 5.Table 2 Localization of metastases and number of
metastatic sites in 241 patients with ED SCLC with normal
versus subnormal sodium values.
Serum sodium 135 mmol/l
n Z 183
134 mmol/l
n Z 58
p-value
Metastatic site
CNS 43 (23%) 10 (17%) 0.316
Liver 71 (39%) 32 (55%) 0.028
Adrenal glands 31 (17%) 9 (16%) 0.800
Bone 48 (26%) 22 (38%) 0.087
Lung 44 (24%) 13 (22%) 0.799
Pleura 25 (14%) 15 (26%) 0.030
Number of metastatic sites
1 108 (59.0%) 23 (39.7%) 0.010
2 52 (28.4%) 24 (41.4%) 0.064
3 17 (9.3%) 9 (15.5%) 0.183
4 or more 6 (3.3%) 2 (3.4%) 0.950We looked specifically at patients with severe hypona-
tremia. Sodium values fell during treatment in two
patients. These patients only received one cycle carbo-
platin and etoposid and died within three months. In
another case with early death, follow-up sodium value had
not been assessed. Sodium values increased in all remaining
32 cases (91.4%). Only one patient was symptomatic from
hyponatremia when chemotherapy was initiated. 17
patients received chemotherapy only, 16 patients were
additionally given sodium supplementation. Normal sodium
values were achieved in 28 cases; the values remained
subnormal in 4. Median survival reached 11 months. We did
not use fluid restriction or infusion therapy with higher
concentrations of sodium.
Sodium values returned to normal or slightly subnormal
(>132 mmol/l) in 17 patients (53%) after the first cycle
chemotherapy; 6 of these cases had additionally received
sodium supplementation. Sodium values were normal in
another 5 cases (16%) after 2 cycles chemotherapy (none
with supplementation). Sodium values increased in 7
patients (22%) after 4 cycles chemotherapy, albeit normal
values were seen in only three of these cases. All but one
had been given additional sodium supplementation.Discussion
Hyponatremia resulting from SIADH is one of the most
frequent paraneoplastic syndromes in small cell lung
cancer. Other typical paraneoplastic syndromes in SCLC are
Cushing syndrome, Lambert Eaton Syndrome, dermato-
myositis, anemia and thromboembolism.25Table 4 Log-rank test for median survival (months) in all
patients with SCLC and subset analyses (LD, ED) with sodium
values 135 mmol/l vs. 134 mmol/l.
Sodium value 135 mmol/l
median
survival
134 mmol/l
median
survival
p-value
SCLC, n Z 393a 13.0 9.0 <0.001
SCLC LD, n Z 153 17.0 9.0 0.050
SCLC ED, n Z 240 10.0 9.0 0.135
a Follow-up data are missing in 2 cases.
Figure 1 Median survival in patients with normal
(135 mmol/l) versus subnormal serum sodium values.
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are the most frequent finding in laboratory panels of
patients with SCLC.
Hyponatremia was detected in 18.9% of all patients with
SCLC; severe hyponatremia was present in 8.8%.
According to our results, Hyponatremia seems to be an
indicator for higher tumor burden as a consistent, albeit
non-significant trend toward more metastatic sites was
present in the 58 ED SCLC cases with subnormal sodiumTable 5 Multivariate Cox regression analyses in 393 cases
performed separately for LD and ED SCLC.
Stage Significance HR 95.0%
Confidence
interval
Lower Upper
Limited
disease
Age 0.125 1.015 0.996 1.036
Gender 0.177 1.292 0.891 1.876
LDH 0.112 1.340 0.934 1.921
PS 0.106 1.644 0.900 3.000
Serum
sodium,
per 1
mmol/l
0.025 0.960 0.925 0.995
Extensive
disease
Age 0.840 1.002 0.983 1.021
Gender 0.138 1.225 0.937 1.603
LDH 0.041 1.347 1.012 1.794
PSre 0.000 2.209 1.578 3.091
Serum
sodium,
per 1
mmol/l
0.038 0.979 0.959 0.999values. Interestingly, there were significantly more patients
with liver metastasis in this group.
Response rate was not statistically different in patients
with hyponatremia but there were significantly more cases
with progressive disease as result of first-line therapy (22.7
vs 13.8%, p Z 0.054). This observation might be indicative
for more aggressive tumor biology when hyponatremia is
present.
These findings are in line with other reports on hypo-
natremia in SCLC. Interestingly, similar results were found
in our analysis on LDH as prognostic factor in the same
patient population.14
Following our statistical analyses, there seems to be an
association between hyponatremia and reduced survival.
Analysis of the whole population showed 9 months median
survival versus 13 months (p  0.001). Subset analyses
yielded significantly reduced median survival in cases with
LD SCLC (9 vs. 17 months, p Z 0.050) and a weak trend
toward reduced median survival in ED SCLC (9 vs. 10
months, p Z 0.135). After adjustment for known
confounders, hyponatremia was a significant predictor for
survival in both patients with ED and LD SCLC.
Treatment options for patients with subnormal sodium
values are fluid restriction or sodium supplementation.26
Tolvaptan, a selective oral vasopressin V2-receptor antago-
nist was assessed in patients with chronic heart failure and
led to increased urine production and normalization of
sodium values without needing to adhere to fluid restric-
tion.27 EMEA approved tolvaptan for treatment of hypona-
tremia from SIADH in 2009. Treatment costs are still high and
might impede a more widespread use of this new approach.
50% of our patients with severe hyponatremia received
sodium supplementation in addition to chemotherapy.
Normal sodium values could be restored in 91.4% of these
cases. Normal sodium values could be achieved in 69% after
one or two cycles chemotherapy. Increasing sodium values
were observed in another 22% after cycles. Median survival
reached 11 months. However, Patients with falling sodium
values despite adequate treatment were prone to
rapid disease progression with median survival below three
months.
Due to the retrospective nature of the study some
limitations might apply. On the other hand, the single-
institution design was favorable as all sodium values were
obtained with the same laboratory equipment. Addition-
ally, we evaluated virtually all patients seen over the
mentioned 5-year period and only lost two cases for follow-
up after conclusion of chemotherapy.
In conclusion, Hyponatremia as clinical presentation of
paraneoplastic SIADH is an easily obtainable strong prog-
nostic factor in patients with small cell lung cancer. The
independent level of hyponatremia was confirmed by
statistical adjustment for the two other most important
predictive markers: extend of disease and clinical perfor-
mance status.
Results of multivariate analyses showed LDH levels,
disease stage, performance status and gender to be other
variables which also were statistically proven to be signifi-
cant as prognostic factors.
However, it should be considered that elevated LDH
levels are more common in patients with SCLC and thus are
more useful as prognostic factor.
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